PLK1/BRD4-IN-5

• UNSPSC Description:

  PLK1/BRD4-IN-5 (Compound SC10) is an orally active PLK1 and BRD4 inhibitor with IC50 values of 0.3  nM and 60.8  nM, respectively. PLK1/BRD4-IN-5 can induce MV4-11 cell block in S phase and apoptosis) in a dose-dependent manner. PLK1/BRD4-IN-5 can be used in cancer research[1].

• Target Antigen:

  Apoptosis; Epigenetic Reader Domain; Polo-like Kinase (PLK)

• Type:

  Reference compound

• Related Pathways:

  Apoptosis;Cell Cycle/DNA Damage;Epigenetics

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/plk1-brd4-in-5.html

• Solubility:

  DMSO : 100 mg/mL (ultrasonic)

• Smiles:

  CC[C@@H]1C(N(C2=CN=C(N=C2N1C3CCCC3)NC4=C(C=C5C(CCN5C(CN6C[C@@H](N[C@@H](C6)C)C)=O)=C4)OC)C)=O

• Molecular Weight:

  576.73

• References & Citations:

  [1]Liu J, et al. Discovery and optimization of dihydropteridone derivatives as novel PLK1 and BRD4 dual inhibitor for the treatment of cancer. Bioorg Med Chem. 2024;101:117

• Shipping Conditions:

  Room Temperature

• Clinical Information:

  No Development Reported